Civilization Ventures Announces Portfolio Exit with Acquisition of Singular Bio by Invitae (NASDAQ: NVTA)
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Business Wire
Singular Bio, Inc. (“Singular Bio”) is a privately held company developing single molecule detection technology to enable lower costs and expanded use of high-quality, cell-free DNA analysis, initially for application in non-invasive prenatal screening (NIPS). Invitae, Inc. is a medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Civilization Ventures is a deep tech venture capital firm that has backed dozens of innovative private companies since its inception in 2017, including Singular Bio and Rocket Pharma (NASDAQ: RCKT) SAN FRANCISCO--(BUSINESS WIRE)-- Civilization Ventures is announcing its second portfolio exit in its third year of operations with the acquisition of Singular Bio, a private company developing novel techno
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $53.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch [Seeking Alpha]Seeking Alpha
RCKT
Earnings
- 2/26/24 - Beat
RCKT
Sec Filings
- 4/24/24 - Form 4
- 4/22/24 - Form 144
- 4/17/24 - Form PRE
- RCKT's page on the SEC website